Pfizer Overcomes Attempt To Block Lexiscan ANDA
US Court Denies Astellas’ Motion For Preliminary Injunction
Injunctive relief has been provided against Hospira’s regadenoson ANDA product only until early October, allowing the US-based generics sponsor to close in on a potential launch.
You may also be interested in...
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.
Amphastar has become the fifth firm to receive FDA approval for generic regadenoson, but the exact launch date for the firm and its other generic competitors remains uncertain.
Biocon Biologics is continuing to rack up the capital needed to close its multi-billion deal for Viatris’ global biosimilars business, with two quick equity investments from parent Biocon Limited as stipulated under its acquisition agreement.